Wacker Chemie AG opens €100m RNA manufacturing site
With the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Consortium led by Evotec enters obesity drug space
Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.
Semarion Ltd. wins Ignite SME award at SLAS Europe
UK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona.
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
SLAS Europe 2024 honours products with most impact
Swiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.
Hornet Therapeutics reports first data of EBV-triggered disease blocker
Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
AstraZeneca puts step into obesity market
Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
LabGenius raises £35m to expand its antibody discovery platform
London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Seed financing for Cellugy A/S
Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.
Obesity: Roche with first clinical data after US$2.7bn deal
Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.